SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market participants are bracing for volatility surrounding a scheduled prime-time address from President Trump regarding the ongoing conflict in Iran, with the community sharply divided between expectations of a 'buy the rumor, sell the news' event and fears of a deeper escalation involving ground troops. Traders are closely monitoring the potential for significant moves in oil and equity indices as the market attempts to decipher whether the administration is signaling a strategic withdrawal or a major military shift.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community fixate on the former President's aggressive rhetoric regarding military escalation in Iran, fueling intense debate over his geopolitical strategy and its impact on the markets. While supporters view his strong posture as a necessary display of dominance, critics are actively highlighting contradictions in his messaging and expressing deep concerns over the potential for prolonged conflict and economic instability.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Market participants are intensely focused on the upcoming presidential address regarding the Iran conflict, with community debate split between expecting a major de-escalation announcement and concerns that the speech will merely justify a continued military presence. Traders are closely monitoring the potential for a 'sell the news' reaction following a sharp rally, while active discussions highlight ongoing uncertainty regarding oil supply and the geopolitical stability of the Strait of Hormuz.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to reports that Amazon is in talks to acquire the company, fueling widespread speculation about a potential bidding war involving other major tech players and SpaceX. Community members are actively debating the company's valuation, the strategic value of its spectrum assets in the direct-to-device space, and whether long-term shareholders should hold out for a significant acquisition premium.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing extreme volatility driven by shifting sentiment regarding Middle East geopolitical tensions and conflicting narratives over memory sector demand, specifically related to Google's TurboQuant efficiency research. The community remains deeply divided, with bulls pointing to fundamental growth and potential recovery after a steep pullback, while bears argue the recent parabolic run-up was unsustainable and warn of further technical downside.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors react to conflicting signals surrounding the Iran-U.S. conflict, with the community actively debating whether recent diplomatic overtures are genuine moves toward de-escalation or tactical market manipulation ahead of an upcoming national address. Despite volatility, traders remain focused on the strategic importance of the Strait of Hormuz and the potential for a sustained geopolitical energy risk premium.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company's decision to move its earnings release date to April 1st, fueling intense community debate over potential catalysts versus further share dilution. Bullish sentiment remains tied to speculation surrounding US cannabis rescheduling and a potential CBD pilot program, while critics point to concerns over management's history of acquisitions and the ongoing impact of share offerings.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph (HBAR) is currently a focal point for investors closely monitoring institutional adoption and the potential passage of the Clarity Act, which many believe will provide the regulatory framework necessary for enterprise-grade ledger utility. While the community expresses frustration over recent price consolidation and dilution concerns, long-term holders remain focused on the potential for institutional rerating as the broader market rotates toward verifiable real-world assets and foundational network infrastructure.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors weigh anticipation for upcoming Q1 delivery results against broader market volatility and speculation surrounding a potential SpaceX IPO. Community discourse remains deeply divided between bullish sentiment regarding the company's long-term autonomy and robotics roadmap, and intense bearish concerns over slowing EV demand and high-profile geopolitical tensions.

Launchr is a programmable creator fee engine designed to adapt to every stage of a token’s lifecycle.  Instead of hard coded splits or one time choices, Launchr lets creators dynamically route fees in real time based on market conditions, liquidity depth, and strategy.

Launchr

Investors are actively debating the viability and longevity of the token amidst high-energy launch promotion and community efforts to drive trading volume. While some participants focus on the excitement of early-stage momentum, others are voicing caution regarding the sustainability of these types of market movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8% - Here's Why

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 12.8% - Here's What Happened...

<ul class="summary-bullets"><li>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.</li><li>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40.</li><li>Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail interest on Tuesday on the heels of the company announcing long-term results from its late-stage clinical trials in moderate-to-severe hidradenitis suppurativa.On Stocktwits, retail sentiment around MLTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/649036046</stembedurl>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.Another user said that they are eyeing the stock breaching $19 levels.<stembedurl>https://www.stocktwits.com/Mr_GA/message/649091749</stembedurl>Yet another lauded the stock as the “Best buy in clinical biopharma,” while adding that it guarantees a “massive payday.”<stembedurl>https://www.stocktwits.com/Creisi/message/649090006</stembedurl><h2 class="st-heading-2">MoonLake’s Recent Data Reveal</h2>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving 75% reduction in abscess and inflammatory nodule count. Hidradenitis suppurativa (HS) is a chronic, noncontagious inflammatory skin condition causing painful, recurring lumps and abscesses, often leading to scarring and tunnels under the skin.According to MoonLake, the data sets a new standard in long-term lesion control of HS as approved drugs only reported similar reduction in symptoms for about 40% and 60% of subjects, respectively, at the 1-year mark of their respective pivotal trials.Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.According to data from Koyfin, 12 of the 16 analysts covering MLTX rate it ‘Buy’ or higher while two rate ‘Hold’ and the remaining two rate it ‘Sell.’ The 12-month average price target on the stock is at $26.71, representing a potential upside of about 41%.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> slumped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.

Equity

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.


MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%  - Here's What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 8.7% - Here's What Happened...

Research Analysts Issue Forecasts for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a report released on Monday, March 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research

BTIG Research reissued a "buy" rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday...

<ul class="summary-bullets"><li>Middle East tensions entered a fifth week, with new Houthi involvement and additional U.S. troop deployments raising fears of broader escalation.</li><li>Iran warned ships transiting the Strait of Hormuz could face a “harsh response,” while vessels were reportedly turned away and a cargo ship struck in the waterway.</li><li>The Dow entered correction territory on Friday as major U.S. indexes extended losses and the S&amp;P 500 posted its fifth straight weekly decline.</li></ul>U.S. stock futures slipped late Sunday as escalating tensions in the Middle East and renewed threats to global oil supply kept investors cautious after the Dow entered correction territory and Treasury yields pushed toward fresh highs.As of 9.15 p.m. ET, Dow and Nasdaq 100 futures were down 0.7%, while S&amp;P 500 futures were down by 0.6%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘extremely bearish’ amid ‘high’ message volume, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘bearish’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>Markets reacted to intensifying Middle East tensions as the conflict entered its fifth week, with Iran-backed Houthi militants joining the fight and 3,500 additional U.S. troops arriving in the region. Israel struck Tehran again over the weekend while Saudi Arabia intercepted nearly a dozen drones.Iran’s Revolutionary Guard said movement through the Strait of Hormuz would face a “harsh response,” while Chinese vessels were&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.aastocks.com/en/mobile/news.aspx?newsid=NOW.1513558&amp;newstype=71&amp;newssource=AAFN">reportedly</a> turned away, and a Thai-flagged cargo ship struck in the waterway ran aground. The chokepoint typically handles roughly one-fifth of the global oil supply.Tehran has also decided to formalize control over traffic through the strait by restricting passage to most vessels while allowing only limited shipments from select countries.Brent crude previously settled at $112.57 per barrel and West Texas Intermediate crude at $99.64, their highest close since July 2022. Oil later surged above $116 in early Monday trading after Houthi forces launched missiles at Israel and warned operations would continue until attacks on Iran cease.The Houthis’ entry into the conflict raised concerns the Red Sea and Bab el-Mandeb corridor could become additional pressure points for global shipping routes, potentially tightening supply further. Macquarie analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uso-batl-tpet-premarket-brent-record-month-macquarie-200-oil-risk/cZ3uUGwRIlq">warned</a> oil could reach $200 per barrel if the conflict extends through June while the Strait of Hormuz remains shut.Gary Black, managing partner at The Future Fund,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/garyblack00/status/2037923811379827127">said on X</a> that Saudi Arabia’s East-West Yanbu pipeline is currently operating at its full 7 million barrels-per-day capacity, partially offsetting the roughly 15 million barrels per day that typically transit Hormuz. He added that the Houthis’ entry into the war increases the risk the Red Sea could become “a new front in the conflict.”U.S. equities extended their recent slide on Friday, with all three major indexes posting sharp losses as the Dow entered correction territory and the S&amp;P 500 marked a seven-month low, capping a fifth straight weekly decline for the benchmark:<figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>−1.73%</td><td>45,166.64</td></tr><tr><td>S&amp;P 500</td><td>−1.67%</td><td>6,368.85</td></tr><tr><td>Nasdaq Composite</td><td>−2.15%</td><td>20,948.36</td></tr></tbody></table></figure>Investor sentiment remained cautious even after U.S. President Donald Trump extended a deadline for potential strikes on Iran’s energy infrastructure to April 6 while signaling negotiations were continuing.John Spencer, executive director of the Urban Warfare Institute,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/SpencerGuard/status/2038110363749872014">said on X</a> that expectations that the conflict would require a full-scale ground invasion of Tehran reflect “shallow thinking rooted in outdated and often biased mental models of war,” adding that the campaign is focused on degrading Iran’s military capability and forcing behavioral change rather than occupying the capital.<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>AleAnna (ANNA): Shares jumped nearly 20% overnight late Sunday as Middle East tensions disrupted global LNG flows and pushed European gas prices higher, drawing attention to the company’s expanding Po Valley reserves as Europe faces tighter storage levels ahead of winter.Microsoft (MSFT): Shares are on track for their sixth straight month in the red as analysts warned next-generation PlayStation and Xbox consoles could launch near the $1,000 level amid rising memory costs and tariff-related pricing pressure.MoonLake Immunotherapeutics (MLTX): Shares rose more than 4% in overnight trading after the company reported strong&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-sonelokimab-phase-3-hidradenitis-suppurativa-week-40-data/cZEREqORIZE">Phase 3 trial results</a> for its lead skin disease drug Sonelokimab, with about 62% of patients showing major symptom improvement and no new safety concerns reported.Ondas Holdings (ONDS): Shares fell to their lowest levels in three months on Friday amid broader market weakness, while Barclays highlighted autonomous drone swarms and “Physical AI” as a major long-term growth shift in defense tech.Reddit (RDDT): Shares fell to their lowest levels since June 2025 after JPMorgan flagged slowing U.S. visitor growth in third-party data and warned geopolitical tensions could weigh on digital advertising spending.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note ended last week near 4.44% after rising as high as 4.48%, its highest level since July 2025, as traders reassessed expectations for Federal Reserve policy.The Kobeissi Letter&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/KobeissiLetter/status/2038252667365920831">said on X</a> that the bond market is approaching crisis levels last seen during “Liberation Day” in April 2025 and warned yields could push above 4.5% without intervention, adding that history suggests some form of “attempted bond market intervention is coming.”The publication&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/KobeissiLetter/status/2038336485003522487">added</a> that global long-term bonds saw $4.7 billion in weekly outflows, the second-largest on record, while high-yield funds logged a third straight weekly withdrawal totaling $13.5 billion.&nbsp;Meanwhile, gold traded near $4,490 per ounce. The Kobeissi Letter&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/KobeissiLetter/status/2038044256527323371">said on X</a> that 95% of stocks in the VanEck Gold Miners ETF (GDX) are now in a bear market, the highest since April 2023, adding that gold miners have “rarely been this oversold.” They also flagged that a similar setup in October 2023 preceded a 346% rally into March 2026.Asian markets were weaker, with the MSCI Asia Pacific Index excluding Japan down 0.3%, while shares in Australia and Japan opened lower.Among Monday’s catalysts, investors will watch remarks from Federal Reserve Chair Jerome Powell and New York Fed President John Williams for signals on the policy outlook.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange (NYSE) on March 02, 2026 in New York City. (Photo by Spencer Platt/Getty Images)

Dow, S&P 500, Nasdaq Futures Slip As Hormuz Risk Deepens In Fifth Week Of Conflict: Why ANNA, MSFT, MLTX, ONDS, RDDT Are In Spotlight

Brent crude climbed above $116, and WTI topped $100 after missile strikes intensified across the Gulf and Red Sea shipping corridors.

<ul class="summary-bullets"><li>The company's week-40 Phase 3 data showed continued improvement in most patients treated with Sonelokimab for hidradenitis suppurativa.</li><li>About 62% of patients showed strong improvement after 40 weeks of treatment, with up to 32% seeing near-complete lesion clearance.</li><li>Up to 25% hit inflammatory remission, while patients also reported reductions in pain and improvements in daily functioning.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. (MLTX) jumped over 6% in overnight trading late Sunday after updated Week-40 Phase 3 data showed continued improvement in most patients treated with Sonelokimab, its lead therapy for hidradenitis suppurativa, an inflammatory skin disease.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> slipped over 2% on Friday but is still on track to post its second straight quarterly gain.<h2 class="st-heading-2">Sonelokimab Shows Strong Week-40 Gains</h2>New data from the Vela-1 and Vela-2 trials showed that 62% of patients treated with Sonelokimab had strong improvement after 40 weeks, while up to 32% saw their skin lesions nearly clear. Up to 25% achieved inflammatory remission, meaning the key signs of the disease disappeared completely.Patients also reported meaningful improvements in pain, movement and everyday activities such as walking and getting dressed. Up to 43% experienced a clear reduction in their worst skin pain, and 65% reported overall improvements in quality of life. The treatment’s safety profile remained consistent with earlier studies, with no new safety concerns reported.“The Week 40 results from the VELA trials show an early and increasing clinical benefit over time for patients treated with Sonelokimab, addressing a critical goal in HS treatment: long-term disease control,” said Alexa Kimball, CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center.Momentum Builds Across IndicationsThe update adds to growing momentum for Sonelokimab following positive&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-jumps-overnight-as-spine-drug-trial-win-sets-stage-for-investor-day-showdown/cZRt765R4UX">Phase 2 results</a> last month in axial spondyloarthritis, an inflammatory spine disease.In the S-Olaris trial, 81% of patients showed improvement within 12 weeks, supported by imaging evidence of reduced joint inflammation and biomarker signals linked to disease activity. The safety profile remained consistent with prior studies.<h2 class="st-heading-2">Runway Extends Ahead Of 2026 Catalysts</h2>MoonLake ended 2025 with $394 million in cash and marketable securities, alongside proceeds from a recent $75 million equity raise, which the company expects will support operations into the second half of 2027. It also expanded its Hercules Capital facility, providing access to up to $400 million in additional non-dilutive funding.Investors are now watching several catalysts this year, including 52-week data from the Phase 3 Vela trials in hidradenitis suppurativa in the second quarter, results from the Phase 3 Izar-1 trial in psoriatic arthritis in mid-2026, a biologics license application submission for hidradenitis suppurativa in the second half of 2026, and results from the Phase 3 Izar-2 trial later in the second half of 2026.<h2 class="st-heading-2">What Is The Retail Mood On Stocktwits?</h2>On Stocktwits, retail sentiment for MLTX was ‘extremely bullish’ amid nearly an 800% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_8d7af6c9b8.webp" alt="mltx ss.png" width="970" height="141"><figcaption>MLTX sentiment and message volume as of March 29 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Creisi/message/648866581">said</a>, “MLTX's SLK is now the "Gold Standard" in HS treatment if a doctor actually cares about curing this debilitating disease!”<stembedurl>https://stocktwits.com/Creisi/message/648866581</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/JTMinor1/message/648858770">pointed</a> to the trial results and said, “This is going to be GREAT!!! But Monday is going to be volatile with all the shorting hedgehogs and gamma chasers trying to reset their positions.”<stembedurl>https://stocktwits.com/JTMinor1/message/648858770</stembedurl>MLTX stock has declined nearly 60% over the past year, but is up over 30% since January.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tom-lee-said-crypto-winter-will-end-in-april-clock-s-ticking-bitcoin-isn-t/cZ3CnbjRIZ5">March’s Almost Over — Can Bitcoin Still Meet Tom Lee’s April Call?</a>

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving

Momentum for Sonelokimab builds after positive Phase 2 S-Olaris spine disease results, where 81% of patients improved within 12 weeks.

This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday

Top Wall Street analysts upgraded APA Corp. & MoonLake Immunotherapeutics, see why & what other analysts think on our analyst ratings page.read more...

Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"

Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and set a $24.00 target price for the company in a report on Monday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Stocktwits

Stocktwits Polls

MoonLake Immunotherapeutics

Investors are closely analyzing a Form 144 filing by BVF Partners, debating if the 3.75 million share divestment is a bearish sign or a routine liquidity move.

The community remains hyper-focused on the potential for a high-premium buyout, citing the drug's strong clinical profile as a key valuation driver.

Traders are coordinating to push the stock above $19 to trigger a potential gamma hedge, aiming to force market makers into buying more shares.

Many retail investors express frustration over what they perceive as deliberate short-selling tactics and institutional price manipulation.

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MLTX News

MLTXMoonLake Immunotherapeutics